期刊文献+

辛伐他汀对肾移植后高脂血症患者RANTES及其受体CCR5 mRNA表达的影响 被引量:1

Effect of simvastatin on expression of RANTES and its receptor CCR5 mRNA in renal transplant recipients with hyperlipidemia
下载PDF
导出
摘要 目的: 探讨肾移植术后高脂血症患者外周血RANTES (regulated on activation normal T-cell expressed and secreted)及其受体CCR5(chemokine receptor 5) mRNA表达及治疗. 方法: 根据患者肾移植术后6~8 mo的血脂水平分血脂正常组(n=30)和血脂增高组(n=30),血脂增高组又根据辛伐他汀治疗时间分1.5 mo治疗组(n=30)和3 mo治疗组(n=30),并设正常对照组(n=30),利用RT-PCR检测各组患者外周血RANTES和CCR5 mRNA表达水平. 结果: 各组肾功能正常,胆固醇酯,三酰甘油,低密度脂蛋白水平均按对照组,血脂正常组,血脂增高组顺序递增(P<0.05),3 mo治疗组较1.5 mo治疗组有显著降低(P<0.05);RANTES及其受体CCR5 mRNA表达水平按对照组,血脂正常组,血脂增高组顺序递增,1.5 mo治疗组和3 mo治疗组均较血脂增高组有显著降低(P<0.05),而3 mo治疗组又明显低于1.5 mo治疗组(P<0.05). 结论: RANTES及其受体CCR5 mRNA表达可能在移植肾慢性损伤早期起作用;高脂血症能加重已增高表达,辛伐他汀治疗可降低表达. AIM: To study whether hyperlipidemia after renal transplantation is related to the expression of RANTES ( regulated on activation normal T-cell expressed and secreted) and its receptor CCR5 (chemokine receptor 5) mRNA in peripheral monocyte cells (PMCs) and to explore its therapy. METHODS: Renal recipients were divided into normal lipidemia group ( n = 30) and hyperlipidemia group (n=30) according to the serum lipid level 6 -8 months after transplantation. The patients in the hyperlipidemia group were treated with simvastatin for 1.5 months ( 1.5-month treatment group) or 3 months (3-month treatment group). The control group consisted of 30 healthy subjects. Serum total cholesterol (TC), triglyceride ( TG ), low-density lipoprotein (LDL), high-density lipoprotein (HDL) were measured and RT-PCR was used to detect the expression of RANTES and CCR5 mRNA in PMCs. RESULTS: The renal function of all the patients was normal. TC, TG, LDL and expression of RANTES and CCR5 mRNA in the normal lipidemia group were lower than those in the hyperlipidemia group, but higher than those in control group ( P 〈 0.05 ), and those in 3-month treatment group were significantly lower than those in 1.5-month treatment group ( P 〈 0.05 ). CONCLUSION: The expression of RANTES and CCR5 mRNA is involved in the early-stage chronic injury of kidney allografts. Hyperlipidemia can strengthen the increased ex- pression of RANTES and CCR5 mRNA. Simvastatin can reduce the expression of RANTES and CCR5 mRNA in the kidney transplant recipients with hyperlipidemia.
出处 《第四军医大学学报》 北大核心 2005年第19期1787-1789,共3页 Journal of the Fourth Military Medical University
关键词 肾移植 高脂血症 RANTES 逆转录聚合酶链反应 辛伐他汀 kidney transplantation hyperlipidemia RAN-TES RT-PCR simvastatin
  • 相关文献

参考文献6

  • 1Pannu HS, Singh D, Sandhu JS. Lipid profile before and after renal transplantationA longitudinal study[J]. Ren Fail, 2003;25(2):411-417.
  • 2舒春兰,周临生,雷小勇,成元桂.氟伐他汀对高脂血症患者的血脂及细胞粘附分子的影响[J].中国动脉硬化杂志,2002,10(1):62-64. 被引量:25
  • 3Bursill CA, Channon KM, Greaves DR. The role of chemokines in atherosclerosis: Recent evidence from experimental models and population genetics[J]. Curr Opin Lipidol, 2004;15(2):145-149.
  • 4Veillard NR, Kwak B, Pelli G, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice[J]. Circ Res, 2004;94(2):253-261.
  • 5Song E, Zou H, Yao Y, et al. Early application of Met-RANTES ameliorates chronic allograft nephropathy[J]. Kidney Int, 2002;61(4):676-685.
  • 6Corsi MM, Leone G, Fulgenzi A, et al. RANTES and MCP-1 chemokine plasma levels in chronic renal transplant dysfunction and chronic renal failure[J]. Clin Biochem, 1999;32(3):455-460.

二级参考文献7

  • 1Hillis GS, Flapan AD. Cell adhesion molecules in cardiovascular disease:a clinical perspective. Heart, 1998, 79(5): 429-431
  • 2Inuzuka H, Seita T, Okamotto K, et al. A sensitive ELISA for the characterization of two forms of circulating intercellular adhesion molecule 1 in human plasma. Bull, 1995, 18: 1 036
  • 3Malini Haria, Donna Mc Tavish. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs, 1997, 53 (2): 299
  • 4Filippo C, Luigi MB, Antonion B, et al. Role of inflammation in the pathogenesis of unstable coronary artery disease. Am J Cardiol, 1997, 80 (5A): 10-16
  • 5Hackman A, Abe Y, Insull W Jr, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation, 1996, 93: 1 334
  • 6Cominacini L, Garbin U, Pasini AF, et al. Antioxidants inhibit the exprssion of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med, 1997, 22: 117
  • 7陈晖,沈潞华,谢苗荣,李东宝.氟伐他汀对内膜损伤后动脉粥样硬化家兔内皮功能的改善作用[J].中国动脉硬化杂志,2000,8(1):39-42. 被引量:11

共引文献24

同被引文献9

  • 1Kalluri R,Neilson EG.Epithelial-mesenchymal transition and its implications for fibrosis[ J ].J Clin Invest,2003,112 (12):1776-1784.
  • 2Abdel wahab N,Mason RM.Connective tissue growth factor and renal diseases:Some answers,more questions[ J].Curr Opin Nephrol Hypertens,2004,13 (1):53-58.
  • 3Strutz F,Okada H,Lo CW,et al.Identification and characterization of a fibroblast marker:FSP1[J].J Cell Biol,1995,130(2):393-405.
  • 4Yang J,Liu Y.Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis[J].Am J Pathol,2001,159(4):1465-1475.
  • 5Yoshida S,Watanabe T,Yoshinaga A,et al.Inflammatory myofibroblastic tumor of the renal pelvis[ J ].Hinyokika Kiyo,2006,52(1):31 -33.
  • 6Becker GJ,Hewitson TD.The role of tubulointerstitial injury in chronic renal failure[ J ].Curr Opin Nephrol Hypertens,2000,9(2):133 -138.
  • 7Qi W,Twigg S,Chen X,et al.Integrated actions of transforming growth factor-betal and connective tissue growth factor in renal fibrosis[ J].Am J Physiol Renal Physiol,2005,288 (4):800-809.
  • 8Wang S,Denichilo M,Brubaker C,et al.Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy[ J].Kidney Int,2001,60(1):96-105.
  • 9张春,朱忠华,邓安国.结缔组织生长因子对人肾小管上皮细胞转分化影响的研究[J].中华肾脏病杂志,2003,19(6):374-377. 被引量:16

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部